Financing to Support Commercial Acceleration of the Tablo® Hemodialysis System, an Enterprise Solution Designed to Reduce the Cost and Complexity of Dialysis
SAN JOSE, Calif., Feb. 4, 2020 /PRNewswire/ -- Outset Medical, a leading medtech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced a $125 million Series E equity financing round led by D1 Capital Partners. Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., also are participating in the financing.
Proceeds will be used to support commercial expansion of Outset Medical's Tablo Hemodialysis System across the acute and chronic care markets in the United States. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided.
Read More: https://www.prnewswire.com/news-releases/outset-medical-announces-125-million-financing-led-by-d1-capital-partners-300998158.html
Via: PR Newswire